Nonsteroidal Anti Inflammatory Drug Articles & Analysis
2 news found
Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...
(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. ...